Skip to main content
Clinical Trials/NL-OMON54216
NL-OMON54216
Recruiting
Phase 3

A placebo-controlled, double-blind randomized trial evaluating the effect of etidronate in young patients with pseudoxanthoma elasticum on ectopic mineralization. - TEMP-PREVENT

niversitair Medisch Centrum Utrecht0 sites76 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Grönblad-Strandberg syndrome
Sponsor
niversitair Medisch Centrum Utrecht
Enrollment
76
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Interventional

Investigators

Sponsor
niversitair Medisch Centrum Utrecht

Eligibility Criteria

Inclusion Criteria

  • In order to be eligible to participate in this study, a subject must meet all
  • of the following criteria:
  • \- Be between 18 years and 55 years.
  • \- Have a definitive diagnosis of PXE according to the Plomp criteria, which
  • confirm a diagnosis of PXE when at least two (or more) criteria not belonging
  • to the same category (skin, eye, genetic) are met:
  • a. Yellowish papules and/or plaques on the lateral side of the neck and/or
  • flexural areas of the body or
  • b. Increase of morphologically altered elastin with fragmentation, clumping and
  • calcification of elastic fibers in a skin biopsy taken.

Exclusion Criteria

  • A potential subject who meets any of the following criteria will be excluded
  • from participation in this study:
  • 1\. Patients that are unable or unwilling to sign for informed consent.
  • 2\. Pregnant, lactating, or fertile women who might wish to become pregnant
  • within three years.
  • 3\. Patients with an estimated glomerular filtration rate below 30 ml/min/1\.73m2
  • according to the CKD\-EPI equation.
  • 4\. Patients with a known abnormality of the oesophagus that would interfere
  • with passage of the drug (e.g. oesophagus stenosis).
  • 5\. Patients with chronic diarrhoea (\> 1 month).

Outcomes

Primary Outcomes

Not specified

Similar Trials